● SK bioscience’s quadrivalent flu vaccine approved by the Ministry of Food and Drug Safety for administration to infants
- SKYCellflu Quadrivalent is now available to vaccinate everyone 6 months or older
- The vaccine is expected to play a leading role in this fall/winter flu vaccine market during the transition to quadrivalent vaccinesSK＇s quadrivalent flu vaccine, of which technology has been recognized worldwide due to the export of its production technology and attainment of WHO (World Health Organization) certification, had its vaccination targets expanded to all age groups.
SK bioscience (CEO Ahn Jae-yong) announced on the 23rd that the company has received approval from the Ministry of Food and Drug Safety for the quadrivalent cell culture flu vaccine, SKYCellflu Quadrivalent, to be administered to infants between 6 months to 3 years of age.
This allows SKYCellflu Quadrivalent to be administered to all age groups 6 months or older.
Last December, SKYCellflu Quadrivalent became the first quadrivalent cell culture-derived flu vaccine to acquire WHO Prequalification. Therefore, the vaccine is expected to gain momentum in the domestic market and expand sales overseas.
Also, considering that a seasonal flu epidemic overlapping the COVID-19 pandemic can lead to an overload of the medical system due to the two diseases causing similar symptoms, the vaccine market is expected to expand as quarantine authorities are recommending active influenza vaccination this fall.
Ahn Jae-yong, CEO of SK bioscience, said, “With the approval for infant vaccination, we can now provide this advanced technology of cell culture-derived flu vaccine to all age groups,” and added, “The vaccine is expected to play a leading role in this year＇s flu vaccine market.”
SK bioscience is a vaccine company that was spun off from SK chemicals in July 2008. The company has developed vaccines independently, which include: SKYCellflu, the first cell culture-derived trivalent flu vaccine in Korea, SKYCellflu Quadrivalent, the world＇s first cell culture-derived quadrivalent flu vaccine, SKY Zoster the world＇s second herpes zoster vaccine, and SKY Varicella the second varicella vaccine developed in Korea.
* Photo description: SKYCellflu Quadrivalent, now approved for infants between 6 months to 3 years of age